Xeris To Test Hypothyroidism Candidate In Healthy Subjects, Stock Moves Higher

by Vandana Singh, Benzinga Editor

August 12, 2021 5:36 AM | 29 seconds read |

The FDA has signed off Xeris Pharmaceuticals Inc's XERS Investigational New Drug Application (IND) for its XeriSol levothyroxine (XP-8121) for hypothyroidism.
Xeris will initiate a Phase 1 study to characterize Pharmacokinetics (PK) and evaluate the safety and tolerability of XP-8121 in healthy participants.
Price Action: XERS shares are up 21.7% at $2.86 during the premarket session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.